This proposal constitutes the renewal application of the Pediatric Oncology Clinical Research Training Program (POCRTP), developed by Baylor College of Medicine's Texas Children's Cancer Center. This training program is predicated on the premise that the development of pediatric oncologists and pediatric oncology nurses who are highly trained in clinical research is essential for continued progress to be made in the treatment of childhood cancer. This renewal application highlights the impressive academic accomplishments and progress of the individual Scholars recruited during the last ten years. The program is structured to provide a formal, comprehensive, multidisciplinary clinical research educational program that trains (1) pediatricians who have completed a three-year pediatric hematology-oncology fellowship training program and are board eligible or certified in that subspecialty and, (2) Ph.D. nurses with a career interest in pediatric oncology clinical research. Trainees, in this """"""""one-track"""""""" program, are designated """"""""Paul Calabresi Scholars"""""""". They receive a two to three year comprehensive, didactic mentored training experience in the design, implementation, conduct and analysis of clinical research trials. The program emphasizes training in therapeutic research that occurs in team research settings in which basic and clinical scientists interact to expedite the translation of basic research discoveries into patient-oriented therapeutic cancer research. The program includes participation in a core didactic course in clinical investigation and trial design, provided through Baylor College of Medicine's Clinical Scientist Training Program, and an in-depth clinical research training experience focused in one of five specialized research areas, designated """"""""Pathways"""""""", chosen by the trainee. The POCRTP Pathways include Clinical Pharmacology, Neuro-oncology, Cell and Gene Therapy, Hematologic Malignancy or Solid Tumors. The research experience within each Pathway is tailored to meet the individual Scholar's long-term research goals. All Scholars receive comprehensive mentorship by both a laboratory research and a clinical research mentor and receive in depth instruction in clinical trial design, statistical analysis, research ethics and regulatory requirements and guidelines. In addition, Scholars design and conduct clinical trials in their respective Pathways. An elective rotation at the National Cancer Institute's Cancer Therapy Evaluation Program is a feature of this program. The experience to date indicates that Scholars who complete this program are exceptionally well trained in clinical research, very successful in obtaining NIH funding and well positioned to become future leaders in pediatric oncology clinical research.

Public Health Relevance

This Pediatric Oncology Clinical Research Training Program provides a comprehensive clinical research educational program that trains pediatric oncologists and doctoral-trained pediatric oncology nurses in pediatric oncology clinical research. The program goal is to produce the next generation of leaders in the field of pediatric cancer research. The trainees, designated Paul Calabresi Scholars, receive a mentored training experience in the design, implementation, conduct and analysis of clinical research trials with the ultimate goal of translating basic research discoveries into innovative treatments that will improve the prognosis of children with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA090433-13
Application #
8693597
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
2001-04-01
Project End
2017-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
13
Fiscal Year
2014
Total Cost
$702,951
Indirect Cost
$60,000
Name
Baylor College of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Rau, Rachel E; Dreyer, ZoAnn; Choi, Mi Rim et al. (2018) Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer 65:
Kilburn, Lindsay B; Kocak, Mehmet; Baxter, Patricia et al. (2018) A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer 65:
Stevens, Alexandra M; Miller, Jennifer M; Munoz, Jaime O et al. (2017) Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance. Blood Adv 1:1387-1397
Heczey, Andras; Louis, Chrystal U; Savoldo, Barbara et al. (2017) CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther 25:2214-2224
Rau, Rachel E; Carroll, Andrew J; Heerema, Nyla A et al. (2017) Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia. Br J Haematol 179:843-846
Cooper, Todd M; Sison, Edward Allan Racela; Baker, Sharyn D et al. (2017) A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co Pediatr Blood Cancer 64:
Flores, Ricardo J; Kelly, Aaron J; Li, Yiting et al. (2017) The prognostic significance of circulating serum amyloid A and CXC chemokine ligand 4 in osteosarcoma. Pediatr Blood Cancer 64:
Flores, Ricardo J; Kelly, Aaron J; Li, Yiting et al. (2017) A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG. Cancer 123:144-154
Rau, Rachel E; Rodriguez, Benjamin A; Luo, Min et al. (2016) DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128:971-81
Yang, Liubin; Rodriguez, Benjamin; Mayle, Allison et al. (2016) DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell 29:922-934

Showing the most recent 10 out of 65 publications